Denmark · Delayed Price · Currency is DKK Novo Nordisk Statistics
Total Valuation
Novo Nordisk has a market cap or net worth of DKK 1.31 trillion. The enterprise value is 1.40 trillion.
| Market Cap | 1.31T |
| Enterprise Value | 1.40T |
Important Dates
The last earnings date was Wednesday, August 5, 2026.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | Aug 14, 2026 |
Share Statistics
Novo Nordisk has 4.42 billion shares outstanding. The number of shares has decreased by -0.14% in one year.
| Current Share Class | 3.35B |
| Shares Outstanding | 4.42B |
| Shares Change (YoY) | -0.14% |
| Shares Change (QoQ) | -0.29% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 28.01% |
| Float | 3.17B |
Valuation Ratios
The trailing PE ratio is 11.28 and the forward PE ratio is 14.93. Novo Nordisk's PEG ratio is 6.59.
| PE Ratio | 11.28 |
| Forward PE | 14.93 |
| PS Ratio | 3.97 |
| PB Ratio | 5.91 |
| P/TBV Ratio | 13.17 |
| P/FCF Ratio | 17.23 |
| P/OCF Ratio | 9.91 |
| PEG Ratio | 6.59 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.00, with an EV/FCF ratio of 18.49.
| EV / Earnings | 12.04 |
| EV / Sales | 4.26 |
| EV / EBITDA | 8.00 |
| EV / EBIT | 8.69 |
| EV / FCF | 18.49 |
Financial Position
The company has a current ratio of 0.87, with a Debt / Equity ratio of 0.63.
| Current Ratio | 0.87 |
| Quick Ratio | 0.64 |
| Debt / Equity | 0.63 |
| Debt / EBITDA | 0.80 |
| Debt / FCF | 1.85 |
| Interest Coverage | 1,566.84 |
Financial Efficiency
Return on equity (ROE) is 59.82% and return on invested capital (ROIC) is 39.22%.
| Return on Equity (ROE) | 59.82% |
| Return on Assets (ROA) | 18.73% |
| Return on Invested Capital (ROIC) | 39.22% |
| Return on Capital Employed (ROCE) | 45.35% |
| Weighted Average Cost of Capital (WACC) | 5.58% |
| Revenue Per Employee | 4.94M |
| Profits Per Employee | 1.75M |
| Employee Count | 66,700 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 1.22 |
Taxes
In the past 12 months, Novo Nordisk has paid 32.31 billion in taxes.
| Income Tax | 32.31B |
| Effective Tax Rate | 21.72% |
Stock Price Statistics
The stock price has decreased by -17.16% in the last 52 weeks. The beta is 0.35, so Novo Nordisk's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | -17.16% |
| 50-Day Moving Average | 313.32 |
| 200-Day Moving Average | 299.38 |
| Relative Strength Index (RSI) | 43.01 |
| Average Volume (20 Days) | 4,512,341 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novo Nordisk had revenue of DKK 329.43 billion and earned 116.44 billion in profits. Earnings per share was 26.20.
| Revenue | 329.43B |
| Gross Profit | 270.09B |
| Operating Income | 161.39B |
| Pretax Income | 148.75B |
| Net Income | 116.44B |
| EBITDA | 173.68B |
| EBIT | 161.39B |
| Earnings Per Share (EPS) | 26.20 |
Balance Sheet
The company has 44.98 billion in cash and 140.13 billion in debt, with a net cash position of -95.15 billion or -21.51 per share.
| Cash & Cash Equivalents | 44.98B |
| Total Debt | 140.13B |
| Net Cash | -95.15B |
| Net Cash Per Share | -21.51 |
| Equity (Book Value) | 221.28B |
| Book Value Per Share | 49.97 |
| Working Capital | -30.39B |
Cash Flow
In the last 12 months, operating cash flow was 131.88 billion and capital expenditures -56.04 billion, giving a free cash flow of 75.84 billion.
| Operating Cash Flow | 131.88B |
| Capital Expenditures | -56.04B |
| Depreciation & Amortization | 12.29B |
| Net Borrowing | 36.44B |
| Free Cash Flow | 75.84B |
| FCF Per Share | 17.15 |
Margins
Gross margin is 81.99%, with operating and profit margins of 48.99% and 35.35%.
| Gross Margin | 81.99% |
| Operating Margin | 48.99% |
| Pretax Margin | 45.15% |
| Profit Margin | 35.35% |
| EBITDA Margin | 52.72% |
| EBIT Margin | 48.99% |
| FCF Margin | 23.02% |
Dividends & Yields
This stock pays an annual dividend of 11.70, which amounts to a dividend yield of 3.97%.
| Dividend Per Share | 11.70 |
| Dividend Yield | 3.97% |
| Dividend Growth (YoY) | 0.43% |
| Years of Dividend Growth | 8 |
| Payout Ratio | 44.64% |
| Buyback Yield | 0.14% |
| Shareholder Yield | 4.11% |
| Earnings Yield | 8.91% |
| FCF Yield | 5.80% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Novo Nordisk is 310.82, which is 5.18% higher than the current price. The consensus rating is "Hold".
| Price Target | 310.82 |
| Price Target Difference | 5.18% |
| Analyst Consensus | Hold |
| Analyst Count | 25 |
| Revenue Growth Forecast (3Y) | 1.42% |
| EPS Growth Forecast (3Y) | 1.08% |
Stock Splits
The last stock split was on September 13, 2023. It was a forward split with a ratio of 2.
| Last Split Date | Sep 13, 2023 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Novo Nordisk has an Altman Z-Score of 4.21 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.21 |
| Piotroski F-Score | 5 |